A clinician's guide to drug-drug interactions with direct-acting antiviral agents for the treatment of hepatitis C viral infection

Travis B. Dick, Lance S. Lindberg, Debra D. Ramirez, Michael R. Charlton

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

The US Food and Drug Administration has recently approved a number of new direct-acting antiviral agents for the treatment of chronic hepatitis C virus that have significantly increased the likelihood of a virological cure. These agents are highly effective but present a substantial risk for a host of clinically relevant drug-drug interactions. These interactions must be considered both when starting and stopping any medication, including over-the-counter medications and herbal supplements. These drug-drug interactions can increase the risk of toxicity or decrease the likelihood of treatment response. Knowledge of these interactions is paramount in optimizing the success of antiviral therapy. Conclusion: In this review we summarize the available data regarding drug-drug interactions for direct-acting antiviral agents, the interactions being the most clinically relevant that are currently known; this review is intended to serve as a clinician's guide to understanding and managing these complex interactions. (Hepatology 2016;63:634-643)

Original languageEnglish (US)
Pages (from-to)634-643
Number of pages10
JournalHepatology
Volume63
Issue number2
DOIs
StatePublished - Feb 1 2016
Externally publishedYes

Fingerprint

Virus Diseases
Hepatitis C
Drug Interactions
Antiviral Agents
Pharmaceutical Preparations
Chronic Hepatitis C
Gastroenterology
United States Food and Drug Administration
Hepacivirus
Therapeutics

ASJC Scopus subject areas

  • Hepatology

Cite this

A clinician's guide to drug-drug interactions with direct-acting antiviral agents for the treatment of hepatitis C viral infection. / Dick, Travis B.; Lindberg, Lance S.; Ramirez, Debra D.; Charlton, Michael R.

In: Hepatology, Vol. 63, No. 2, 01.02.2016, p. 634-643.

Research output: Contribution to journalArticle

Dick, Travis B. ; Lindberg, Lance S. ; Ramirez, Debra D. ; Charlton, Michael R. / A clinician's guide to drug-drug interactions with direct-acting antiviral agents for the treatment of hepatitis C viral infection. In: Hepatology. 2016 ; Vol. 63, No. 2. pp. 634-643.
@article{6118828aa013457490f1a41b2dff9f5e,
title = "A clinician's guide to drug-drug interactions with direct-acting antiviral agents for the treatment of hepatitis C viral infection",
abstract = "The US Food and Drug Administration has recently approved a number of new direct-acting antiviral agents for the treatment of chronic hepatitis C virus that have significantly increased the likelihood of a virological cure. These agents are highly effective but present a substantial risk for a host of clinically relevant drug-drug interactions. These interactions must be considered both when starting and stopping any medication, including over-the-counter medications and herbal supplements. These drug-drug interactions can increase the risk of toxicity or decrease the likelihood of treatment response. Knowledge of these interactions is paramount in optimizing the success of antiviral therapy. Conclusion: In this review we summarize the available data regarding drug-drug interactions for direct-acting antiviral agents, the interactions being the most clinically relevant that are currently known; this review is intended to serve as a clinician's guide to understanding and managing these complex interactions. (Hepatology 2016;63:634-643)",
author = "Dick, {Travis B.} and Lindberg, {Lance S.} and Ramirez, {Debra D.} and Charlton, {Michael R.}",
year = "2016",
month = "2",
day = "1",
doi = "10.1002/hep.27920",
language = "English (US)",
volume = "63",
pages = "634--643",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Ltd",
number = "2",

}

TY - JOUR

T1 - A clinician's guide to drug-drug interactions with direct-acting antiviral agents for the treatment of hepatitis C viral infection

AU - Dick, Travis B.

AU - Lindberg, Lance S.

AU - Ramirez, Debra D.

AU - Charlton, Michael R.

PY - 2016/2/1

Y1 - 2016/2/1

N2 - The US Food and Drug Administration has recently approved a number of new direct-acting antiviral agents for the treatment of chronic hepatitis C virus that have significantly increased the likelihood of a virological cure. These agents are highly effective but present a substantial risk for a host of clinically relevant drug-drug interactions. These interactions must be considered both when starting and stopping any medication, including over-the-counter medications and herbal supplements. These drug-drug interactions can increase the risk of toxicity or decrease the likelihood of treatment response. Knowledge of these interactions is paramount in optimizing the success of antiviral therapy. Conclusion: In this review we summarize the available data regarding drug-drug interactions for direct-acting antiviral agents, the interactions being the most clinically relevant that are currently known; this review is intended to serve as a clinician's guide to understanding and managing these complex interactions. (Hepatology 2016;63:634-643)

AB - The US Food and Drug Administration has recently approved a number of new direct-acting antiviral agents for the treatment of chronic hepatitis C virus that have significantly increased the likelihood of a virological cure. These agents are highly effective but present a substantial risk for a host of clinically relevant drug-drug interactions. These interactions must be considered both when starting and stopping any medication, including over-the-counter medications and herbal supplements. These drug-drug interactions can increase the risk of toxicity or decrease the likelihood of treatment response. Knowledge of these interactions is paramount in optimizing the success of antiviral therapy. Conclusion: In this review we summarize the available data regarding drug-drug interactions for direct-acting antiviral agents, the interactions being the most clinically relevant that are currently known; this review is intended to serve as a clinician's guide to understanding and managing these complex interactions. (Hepatology 2016;63:634-643)

UR - http://www.scopus.com/inward/record.url?scp=84956759355&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84956759355&partnerID=8YFLogxK

U2 - 10.1002/hep.27920

DO - 10.1002/hep.27920

M3 - Article

VL - 63

SP - 634

EP - 643

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 2

ER -